2023 annual financial data
TScan Therapeutics 2023 Operating margin
Direct answer
Operating margin was -444%.
Operating income was -93,458,000 USD and net income was -89,218,000 USD.
Operating cash flow was -61,358,000 USD.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 21,049,000 USD
- Operating income
- -93,458,000 USD
- Net income
- -89,218,000 USD
- Operating cash flow
- -61,358,000 USD